DiamiR Biosciences Announces Poster Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)

NEW HAVEN, CT. And MONMOUTH JUNCTION, NJ, June 19, 2024 /PRNewswire/ — DiamiR, a developer of innovative blood diagnostic tests for brain health and other diseases, announced today that it will present a poster at the Alzheimer’s Association International Conference (AAIC), which will be held July 28 – August 1, 2024In Philadelphia, Pennsylvaniaand online.

Poster #95519 titled “Classifier algorithms to characterize different stages of Alzheimer’s disease based on the analysis of circulating microRNAs enriched in the brain and associated with inflammation” will be presented on Monday, July 29, 2024: 8:00 a.m. – 4:15 p.m. EDTin the Pennsylvania Convention Center, Exhibit Hall as part of the AAIC session titled “Topic Development: Biomarkers.”

The company will also hold booth #1431 in the exhibition hall during the conference to highlight its targeted approach aimed at early detection and risk assessment of neurodegenerative diseases and discuss collaboration opportunities.

About the Alzheimer’s Association International Conference

The AAIC is the world’s largest gathering dedicated to advancing dementia science. Each year, the AAIC brings together the world’s leading basic scientists, clinical investigators, early career investigators, clinicians, and members of the healthcare research community to share the latest research discoveries that are expected to lead to methods of prevention and cure. treatment and improvements in the diagnosis of Alzheimer’s disease.

About DiamiR

DiamiR is a private molecular diagnostics company focused on the development of minimally invasive tests for the detection and monitoring of pathologies based on the quantitative analysis of organ-enriched microRNA signatures in plasma for screening, patient stratification, as well as disease progression and treatment monitoring. DiamiR collaborates with leading academic centers, disease-fighting foundations and biopharmaceutical companies. For more information, please visit the Company’s website at www.diamirbio.com.

This press release contains forward-looking statements regarding future events. These statements are predictions and are subject to risks and uncertainties that could cause actual events or results to differ materially.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Contact:
Alidad Mireskandari, PhD
203-570-8275
(email protected)

SOURCE DiamiR